



NDA 21920/S-022

**SUPPLEMENT APPROVAL**

Bionpharma Inc.  
Attention: Usha Sankaran  
Associate Vice President, Regulatory Affairs  
600 Alexander Road  
Suite 2-4B  
Princeton, NJ 08540

Dear Ms. Sankaran:

Please refer to your Supplemental New Drug Application (sNDA) dated and received May 31, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for naproxen sodium capsule, 220 mg.

This “Prior Approval” supplemental new drug application provides for a new instantly redeemable coupon (IRC), \$3 off peel-off sticker, to be to be affixed in the upper left corner of the principle display panels (PDP) for the two previously approved 80-ct cartons and two new approved 80-ct cartons (see table below).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**LABELING**

Submit final printed labeling, as soon as they are available, but no more than 30 days after they are printed. The final printed labeling must be identical to the labeling below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

<b>Submitted Labeling</b>	<b>Date Submitted</b>
“\$3 off” instantly redeemable coupon (IRC) sticker to be placed on cartons for the Naproxen Sodium Capsules 80-ct cartons and for the Naproxen Sodium Capsules 80-ct cartons with Easy Open Arthritis Cap	October 17, 2018
Naproxen Sodium Capsules 80-ct carton without “compare to the active ingredient of ALEVE® Liquid Gels” statement	October 17, 2018
Naproxen Sodium Capsules 80-ct carton with Easy Open Arthritis Cap and without “compare to the active ingredient of ALEVE® Liquid Gels” statement	October 17, 2018

The final printed labeling should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2017, Revision 4)*. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 21920/S-022.**” Approval of this submission by FDA is not required before the labeling is used.

We have additional advice for when preparing your next submission of labeling: follow the guidance for industry entitled: *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* as well as guidances incorporated by reference.  
<https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm333969.pdf>

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tinya Sensie, Regulatory Project Manager at (240) 402-4230.

Sincerely,

*{See appended electronic signature page}*

Karen Murry Mahoney, MD, FACE  
Deputy Director  
Division of Nonprescription Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

KAREN M MAHONEY  
11/29/2018

2